The Patent Finder

Solvay Pharmaceuticals GmbH

Also on record
Records under this name other than patents Solvay Pharmaceuticals GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Solvay Pharmaceuticals GmbH

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,072,256Process for Separating and Determining the Viral Load in a Pancreatin Sample
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,273,348Lipase Variants for Pharmaceutical Use
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,266,607Process for the Manufacture and Use of Pancreatin Micropellet Cores
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,198,871Delayed Release Pancreatin Compositions
Formerly held
In force
 · High confidence
In forceHigh confidence
US 7,232,813Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
Formerly held
Term ended
Term ended Jul 9, 2025 · USPTO record
Term endedTerm ended Jul 9, 2025USPTO record
US 8,802,087Pharmaceutical Compositions of Lipase-Containing Products, in Particular of Pancreatin
Formerly held
Term ended
Term ended Mar 22, 2025 · High confidence
Term endedTerm ended Mar 22, 2025High confidence
US 7,479,378Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity
Term ended
Term ended Sep 25, 2024 · USPTO record
Term endedTerm ended Sep 25, 2024USPTO record
US 8,138,174Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
Formerly held
Lapsed on the fee record
Ended Mar 20, 2024 · USPTO record
Lapsed on the fee recordEnded Mar 20, 2024USPTO record
US 7,202,238Diazabicyclo alkane derivatives with NK1 antagonistic activity
Term ended
Term ended Jan 25, 2024 · USPTO record
Term endedTerm ended Jan 25, 2024USPTO record
US 8,101,619Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
Lapsed on the fee record
Ended Jan 24, 2024 · USPTO record
Lapsed on the fee recordEnded Jan 24, 2024USPTO record
10 of 233 patents shown.
Pro members see all 233.
Pro members: see all 233 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited